hotspot -WSS

hotspot

author：leisure time 2025-10-02 11:07:54 - browse：519

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

WSS

Black vets could get higher VA benefits if race not used in lung test

Former medical device CEO who sold dummy, plastic parts convicted of fraud

The problem with charging patients to message their doctors

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Novo Nordisk obesity pill bests Wegovy in early trial

Amylyx ALS drug failure raises questions and concerns

leisure time

hotspot

focus

What does generative AI mean for health care? We asked experts

As billionaires fund anti

At least 13 dead in Texas as scorching temps continue

Most antidepressants don't work on kids, teens, study finds

Peter Hotez and the public health issue of online harassment

Sepsis can kill a child within hours. Here's how hospitals are fighting back

At least 13 dead in Texas as scorching temps continue

Welsh Carson private equity firm escapes from FTC antitrust case

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

entertainment

Crowdfunding for medical bills sidesteps core problem, author says

The effects of a landmark ruling on DNA ownership are becoming clearer

The problem with charging patients to message their doctors

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Precocious puberty in girls comes with mental health risks

Novel spinal cord stimulator treats paralysis without surgery

hotspot

leisure time

focus

focus